Clinical trials: Chronic Venous Insufficiency
May-Thurner Syndrome, Deep Vein Thrombosis
Venous Stent for the Iliofemoral Vein Investigational Clinical Trial Using the DUO Venous Stent System
This is a prospective, multi-center, single-arm, non-blinded clinical trial designed to investigate the safety and efficacy of the Vesper DUO Venous Stent System as compared to a pre-defined performance goal (PG) established from…
- Conditions
- May-Thurner Syndrome, Deep Vein Thrombosis, Chronic Venous Insufficiency
- Trial name
- VIVID (NCT04580160)
- Testing
- Duo Venous Stent System
- Where
- 30 sites in United States, Poland
- Volunteers
- 162 people
- Sponsor
- Vesper Medical, Inc.
Venous Reflux, Chronic Venous Insufficiency
Venclose digiRF System Post Market Study
A Post-Market, Multi-Center, Prospective, Interventional Study for Treatment of Chronic Venous Disease of the Great and Small Saphenous Veins and Incompetent Perforator Veins.
- Trial name
- NCT05504070
- Testing
- Venclose System (digiRF generator w EVSRF catheter), Venclose MAVEN System (digiRF generator w MAVEN catheter)
- Where
- 7 sites in United States
- Volunteers
- 203 people
- Sponsor
- C. R. Bard
Chronic Venous Insufficiency
Venclose RF Ablation System for the Treatment of IPVs
A feasibility study conducted in patients with incompetent (i.e. refluxing) perforator veins were treated using the Venclose RF Ablation System.
- Trial name
- NCT04386785
- Testing
- Radiofrequency (RF) Thermal Ablation of Incompetent Perforator Veins
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Venclose, Inc.
End Stage Renal Disease, AV Fistula
Safety and Efficacy Study of the Venous Window Needle Guide to Access Arteriovenous (AV)Fistulae
The SAVE Study will evaluate the safety and efficacy of the Venous Window Needle Guide in achieving access of a deep, un-cannulatable arteriovenous fistula to complete hemodialysis as prescribed.
- Conditions
- End Stage Renal Disease, AV Fistula, Kidney Failure
- Trial name
- SAVE (NCT01471041)
- Testing
- Venous Window Needle Guide
- Where
- 2 sites in United States
- Volunteers
- 54 people
- Sponsor
- Vital Access Corp.
Kidney Failure, Chronic, Catheter-Related Infections
Study Assessing Safety & Effectiveness of a Catheter Lock Solution in Dialysis Patients to Prevent Bloodstream Infection
The purpose of this study is determine safety and effectiveness of Neutrolin, a catheter lock solution, for prevention of central venous catheter associated bloodstream infection in hemodialysis patients.
- Trial name
- NCT02651428
- Testing
- Neutrolin, Heparin
- Where
- 5 sites in United States
- Volunteers
- 806 people
- Sponsor
- CorMedix Therapeutics
Chronic Venous Insufficiency, Disease
Study to Evaluate the Efficacy and Tolerability of Venaflon Use in Reducing the Symptoms Caused by Chronic Venous Insufficiency When Compared With Daflon
The objective is to evaluate the effectiveness of the safety of Daflon in decreasing symptoms resulting from chronic venous insufficiency when compared with Daflon.
- Trial name
- NCT01477281
- Testing
- Daflon, Venaflon (Diosmin and Hesperidin)
- Volunteers
- 82 people
- Sponsor
- Laboratório Teuto Brasileiro S/A
Phlebolymphedema, Lymphedema
Clinical Study to Evaluate the Effectiveness and Health Economics of a Novel Portable Non-Pneumatic Active Compression Device (NPCD) for Lymphedema/Phlebolymphedema
An open-label, multi-center, prospective VA study to evaluate the effectiveness and health economics of a Novel Portable Non-Pneumatic Active Compression Device (NPCD) for lymphedema/phlebolymphedema
- Conditions
- Phlebolymphedema, Lymphedema, Chronic Venous Insufficiency
- Trial name
- GRANDE (NCT06418282)
- Testing
- Dayspring
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Koya Medical, Inc.
Chronic Kidney Disease, Hemodialysis Access
Pivotal Study of the Velocity™ pAVF System
This study will evaluate the Velocity Percutaneous Arteriovenous Fistula (pAVF) System, a new minimally invasive method for creating dialysis access.
- Conditions
- Chronic Kidney Disease, Hemodialysis Access, Arteriovenous Fistula, End Stage Renal Disease (ESRD)
- Trial name
- VENOS-3 (NCT07153939)
- Testing
- Velocity Percutaneous Arteriovenous Fistula
- Where
- 13 sites in United States
- Volunteers
- 126 people
- Sponsor
- Venova Medical
Ulcer, Venous Ulcer
ECM and Blood Components for Wound Healing
The Extracellular Matrix (ECM) and Blood Components for Wound Healing feasibility study is a clinical trial approved by Health Canada to study the safety of extracellular matrix (ECM) and autologous blood products in wound…
- Conditions
- Ulcer, Venous Ulcer, Foot Ulcer, Diabetic
- Trial name
- NCT01909908
- Testing
- ECM, Blood Products, ECM in Blood Products
- Where
- Canada
- Volunteers
- 2 people
- Sponsor
- Cook Group Incorporated
Chronic Venous Insufficiency
Efficacy and Safety of Coumarin and Troxerutin in the Symptomatic Treatment of Chronic Venous Insufficiency
The purpose of this study is to evaluate the efficacy and safety of the fixed-dose combination of coumarin and troxerutin versus placebo in the symptomatic treatment of chronic venous insufficiency.
- Trial name
- NCT01848210
- Testing
- Coumarin/troxerutin
- Volunteers
- 829 people
- Sponsor
- Takeda
Venous Insufficiency (Chronic)(Peripheral)
Chronic Venous Insufficiency and Balneotherapy
The aim of this clinical trial is to assess the efficacy of the balneotherapy program (therapeutic orientation: Phlebology) in terms of chronic venous disease improvement and related quality of life, in patients presented with…
- Trial name
- NCT06054737
- Testing
- SPA THERAPY
- Where
- France
- Volunteers
- 64 people
- Sponsor
- CEN Biotech
Chronic Venous Insufficiency
VAP-PRO-C6. Effectiveness and Tolerability of Venoactive Drugs in Combination Therapy in Patients With CVD (CEAP C6)
The VAP-PRO-C6 is a Russian multicenter observational program to be implemented at the routine visits and assessments. The program will include patients with chronic venous disease of CEAP classes C6.
- Trial name
- VAP-PRO-C6 (NCT04757766)
- Testing
- in daily everyday routine practice
- Where
- Russia
- Volunteers
- 350 people, healthy volunteers welcome
- Sponsor
- Servier Russia
Venous Obstruction
RECANA OUS - Recana Thrombectomy Catheter System for Venous Obstruction and Occlusion Study (RECANA-OUS-IRL)
The goal of this clinical investigation is to learn if the Recana Thrombectomy Catheter System can treat chronic venous obstruction and occlusion in participants with symptomatic postthrombotic venous inflow/outflow obstruction.
- Trial name
- NCT07095660
- Testing
- Recana procedure
- Where
- Ireland
- Volunteers
- 20 people
- Sponsor
- Intervene, Inc.
Chronic Venous Insufficiency
SeCure Endovenous Laser Treatment Study
The VenaCure EVLT 400 µm Fiber Kit is currently marketed for the treatment of varicose veins. AngioDynamics, Inc., the company that manufacturers the VenaCure device, is sponsoring this study to assess the safety and…
- Trial name
- SeCure (NCT02215369)
- Testing
- VenaCure EVLT 400 µm fiber Procedure Kit
- Where
- 7 sites in United States
- Volunteers
- 112 people
- Sponsor
- Angiodynamics, Inc.
Multiple Sclerosis, Relapsing-Remitting
A Study of Allogeneic Human UC-MSC and Liberation Therapy (When Associated With CCSVI) in Patients With RRMS
STUDY OBJECTIVES: Primary Objective: Assessment of treatment safety based on incidence of any treatment emergent/treatment associated adverse events prior to discharge and at 1, 3, 6 and 12 months post treatment.
- Trial name
- NCT02587715
- Testing
- Allogeneic Human Umbilical Cord Tissue-Derived Mesenchymal Stem Cells, Liberation therapy
- Where
- Trinidad and Tobago
- Volunteers
- 69 people
- Sponsor
- Novo Cellular Medicine Institute LLP
Venous Leg Ulcer
Effect of VarIthena on Wound Healing in Venous Leg Ulcers (VLU)
A 12 month, multicenter, open-label registry to observe chronic venous insufficiency resulting in VLU treated with Varithena.
- Trial name
- VIEW-VLU (NCT03257254)
- Testing
- Varithena
- Where
- 14 sites in United States, Canada
- Volunteers
- 76 people
- Sponsor
- Boston Scientific Corporation
Lymphedema, Lymphedema Lower Extremity
Study to Evaluate the Safety and Effectiveness of Dayspring for Lower Extremity Lymphedema
A Non-randomized, Open-Label Study to Evaluate the Safety and Effectiveness of Koya Dayspring Active Wearable Compression Technology for Treating Lower Extremity Lymphedema
- Conditions
- Lymphedema, Lymphedema Lower Extremity, Chronic Venous Insufficiency, Secondary Lymphedema
- Trial name
- TIBER (NCT04897035)
- Testing
- Dayspring Active Wearable Compression System
- Where
- 2 sites in United States
- Volunteers
- 24 people
- Sponsor
- Koya Medical, Inc.
Venous Insufficiency
Efficacy and Tolerability CVI (A 12-week, Double-blind, Randomised, Placebo-controlled, Multicentre Trial (CVI)
To determine efficacy and tolerability of Antistax 360 mg tablets in chronic venous insufficiency linked to edema (swelling) and subjective symptoms
- Trial name
- NCT00292435
- Testing
- Read vine leaf extract (AS 195)
- Where
- 16 sites in Austria, Czechia and 1 more
- Volunteers
- 202 people
- Sponsor
- Boehringer Ingelheim
Deep Vein Thrombosis, Post-thrombotic Syndrome
Treatment of Chronic Deep Vein Thrombosis (DVT) and Post-Thrombotic Syndrome (PTS) With the EkoSonic® Endovascular System
To evaluate the efficacy of ultrasound accelerated thrombolysis using the EkoSonic® Endovascular System with standard infusion of thrombolytic drug for post-thrombotic syndrome from chronic venous occlusion.
- Trial name
- ACCESS PTS (NCT02159521)
- Testing
- EkoSonic® Endovascular System, Alteplase
- Where
- 22 sites in United States
- Volunteers
- 81 people
- Sponsor
- Boston Scientific Corporation
Venous Insufficiency
Assess the Efficacy and Tolerability of Antistax Film-coated Tablets in Patients With Chronic Venous Insufficiency
To assess the efficacy and tolerability of Antistax film coated tablets in patients with chronic venous insufficiency (CVI, CEAP Classification: Clinical class 3 and 4a).
- Trial name
- NCT00855179
- Testing
- Red vine leaf extract (AS 195)
- Where
- 20 sites in Germany
- Volunteers
- 250 people
- Sponsor
- Boehringer Ingelheim